Xoán Carbón

Xoán Carbón

Auto-generated profile, based on publicly available information

Xoán Carbón

Energy Control, Associació Benestar i Desenvolupament, 08041 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in International Journal of Drug Policy
Verified
Journal Article
Closed access
PQPol Quintana
Pol Quintana
MVMireia Ventura
Mireia Ventura
MGMarc G Grifell
Marc G Grifell
APAlvaro Palma
Alvaro Palma
LGLiliana Galindo
Liliana Galindo
MTMarta Torrens
Marta Torrens

1 May 2017 in Human Psychopharmacology: Clinical and Experimental
Verified
Journal Article
Closed access
PDF file
MGMarc G Grifell
Marc G Grifell
MVMireia Ventura
Mireia Ventura
XCXoán Carbón
Xoán Carbón
PQPol Quintana
Pol Quintana
LGLiliana Galindo
Liliana Galindo
MTMarta Torrens
Marta Torrens

24 July 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DFD. Fabregat-Safont
D. Fabregat-Safont
XCX. Carbón
X. Carbón
MVM. Ventura
M. Ventura
IFI. Fornís
I. Fornís
EGE. Guillamón
E. Guillamón
MMMARIA IBAÑEZ MARTINEZ
MARIA IBAÑEZ MARTINEZ
New psychoactive substances have been rapidly growing in popularity in the drug market as non-illegal drugs. In the last few years, an increment has been reported on the use of synthetic alternatives to heroin, the synthetic opioids. Based on the information provided by the European Monitoring Centre for Drug and Drug Addiction, these synthetic opioids have been related to overdoses and deaths in Europe and North America. One of these opioids is the U-47700. A few months ago, U-47700 was scheduled in the U.S. and other countries, and other opioid derivatives have been appearing in order to replace it. One of these compounds is U-49900, an analog of U-47700. A white powder sample was obtained from an anonymous user in Spain. After an accurate characterization by gas chromatography-mass spectrometry, ultra-high performance liquid chromatography-high resolution mass spectrometry, nuclear magnetic resonance and single-crystal X-ray diffraction; and complemented by Fourier-transformed infrared spectroscopy, ultraviolet and circular dichroism spectrophotometry, the drug sample was unequivocally identified as U-49900. The information provided will be useful for the Early Warning System and forensic laboratories for future identifications of the U-49900, as well as in tentative identifications of other related opioids.

17 August 2021 in Biology
Verified
Journal Article
Open access
PDF file
LPLourdes Poyatos
Lourdes Poyatos
EFEsther Papaseit Fontanet
Esther Papaseit Fontanet
EOEulalia Olesti
Eulalia Olesti
CPClara Pérez-Mañá
Clara Pérez-Mañá
MVMireia Ventura
Mireia Ventura
MFMagi Farré
Magi Farré
Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or published intoxication reports. In the present observational–naturalistic study, we evaluate the acute subjective and physiological effects of methylone after oral self-administration in comparison to MDMA in healthy poly-drug users. Fourteen participants (10 males, 4 females) selected their single oral doses of methylone from 100 to 300 mg (n = 8, mean dose 187.5 mg) or MDMA from 75 to 100 mg (n = 6, mean dose 87.5 mg) based on their experience. Study variables were assessed at 0, 1, 2, and 4 h (h) and included vital signs (non-invasive blood pressure, heart rate, cutaneous temperature) and subjective effects using visual analogue scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI) short form, and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire. Additionally, oral fluid concentrations of methylone and MDMA were determined. Acute pharmacological effects produced by methylone followed the prototypical psychostimulant and empathogenic profile associated with MDMA, although they were less intense. Methylone concentrations in oral fluid can be considered a useful biomarker to detect acute exposure in oral fluid. Oral fluid concentrations of MDMA and methylone peaked at 2 h and concentrations of MDMA were in the range of those previously described in controlled studies. Our results demonstrate that the potential abuse liability of methylone is similar to that of MDMA in recreational subjects.

9 May 2018 in Forensic Toxicology
Verified
Journal Article
Closed access
PDF file
DFDavid Fabregat-Safont
David Fabregat-Safont
XCXoán Carbón
Xoán Carbón
CGCristina Gil
Cristina Gil
MVMireia Ventura
Mireia Ventura
JSJuan V. Sancho
Juan V. Sancho
MMMARIA IBAÑEZ MARTINEZ
MARIA IBAÑEZ MARTINEZ

2 December 2020 in Addiction Biology
Verified
Journal Article
Closed access
PDF file
DFDavid Fabregat‐Safont
David Fabregat‐Safont
MBManuela Barneo-Muñoz
Manuela Barneo-Muñoz
XCXoán Carbón
Xoán Carbón
FHfelix hernandez hernandez
felix hernandez hernandez
FMFerran Martínez-García
Ferran Martínez-García
MMMARIA IBAÑEZ MARTINEZ
MARIA IBAÑEZ MARTINEZ